GlassScriptPhysician profile
Jessica Coller Ochsner
NPI 1164411161
$11,558.98
in general payments reported to CMS, 2019-2025
39 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $1,099 · 2021: $1,733 · 2022: $1,594 · 2023: $1,854 · 2024: $2,059 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,437 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,437.00 |
| Education | $273.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,021.90 | 2019-2025 | |
| Abbvie INC. | $1,269.84 | 2019-2025 | |
| Pfizer INC. | $764.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $680.75 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $675.91 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Ucb, INC. | $602.27 | 2019-2024 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $593.00 | 2019-2025 | |
| Janssen Biotech, INC. | $590.90 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $461.27 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $434.04 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $432.26 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $334.41 | 2021-2025 | Adbry |
| Sanofi-Aventis U.S. LLC | $278.98 | 2020-2022 | |
| Hill Dermaceuticals, INC. | $273.37 | 2021-2023 | Tolak |
| Dermavant Sciences, INC. | $253.07 | 2023-2024 | Vtama |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $250.51 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $214.08 | 2019-2023 | Arazlo, Jublia |
| Incyte Corporation | $202.70 | 2022-2025 | Opzelura |
| Dermira, INC. | $189.87 | 2019-2020 | |
| Almirall LLC | $128.10 | 2019-2025 | Klisyri, Seysara |
| Vyne Pharmaceuticals INC. | $126.09 | 2021 | |
| Mallinckrodt Hospital Products INC. | $119.97 | 2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.33 | 2023-2025 | Spevigo, Cyltezo |
| Organon LLC | $79.22 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $63.06 | 2023-2024 | Zoryve |
| Journey Medical Corporation | $55.31 | 2022-2024 | |
| Allergan, INC. | $45.66 | 2020-2022 | |
| Epi Health, LLC | $45.10 | 2019 | |
| Celgene Corporation | $43.43 | 2019 | |
| Galderma Laboratories, L.P. | $43.34 | 2022-2025 | Nemluvio |
| Organogenesis INC. | $37.00 | 2024-2025 | Novachor, Affinity |
| Kerecis Limited | $30.67 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Taro Pharmaceuticals USA, INC. | $24.82 | 2019 | |
| Krystal Biotech INC | $22.39 | 2023 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $22.34 | 2023 | Ycanth |
| Botanix Sb INC | $20.70 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $18.45 | 2025 | Nuzyra |
| Aclaris Therapeutics, INC. | $12.70 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $5.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Ochsner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.